First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
Open Access
- 28 April 2011
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 23 (2), 531-536
- https://doi.org/10.1093/annonc/mdr126
Abstract
Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma. Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m2 days 1–7 orally and bevacizumab 10 mg/kg body weight i.v. day 1 every 2 weeks until disease progression or unacceptable toxicity. The primary end point was disease stabilisation rate [complete response (CR), partial response (PR) or stable disease (SD)] at week 12 (DSR12); secondary end points were best overall response, PFS, overall survival (OS) and adverse events. Sixty-two patients (median age 59 years) enrolled at nine Swiss centres. DSR12 was 52% (PR: 10 patients and SD: 22 patients). Confirmed overall response rate was 16.1% (CR: 1 patient and PR: 9 patients). Median PFS and OS were 4.2 and 9.6 months. OS (12.0 versus 9.2 months; P = 0.014) was higher in BRAF V600E wild-type patients. The primary end point was surpassed showing promising activity of this bevacizumab/temozolomide combination with a favourable toxicity profile. Response and OS were significantly higher in BRAF wild-type patients.Keywords
This publication has 24 references indexed in Scilit:
- Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanomaCancer, 2008
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Preliminary Results of the Combination of Bevacizumab and Weekly Paclitaxel in Advanced MelanomaOncology, 2008
- Modeling Genomic Diversity and Tumor Dependency in Malignant MelanomaCancer Research, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanomaZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant MelanomaAnnals of Surgical Oncology, 2007
- Detection of BRAF V600E Mutation in Colorectal Cancer: Comparison of Automatic Sequencing and Real-Time Chemistry MethodologyThe Journal of Molecular Diagnostics, 2006
- Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanomaCancer, 2006
- Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic MelanomaJournal of Clinical Oncology, 2003